192 related articles for article (PubMed ID: 21565270)
1. Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.
Rajendra Prasad VV; Peters GJ; Lemos C; Kathmann I; Mayur YC
Eur J Pharm Sci; 2011 Jul; 43(4):217-24. PubMed ID: 21565270
[TBL] [Abstract][Full Text] [Related]
2. Chloro acridone derivatives as cytotoxic agents active on multidrug-resistant cell lines and their duplex DNA complex studies by electrospray ionization mass spectrometry.
Rajendra Prasad VV; Venkat Rao J; Giri RS; Sathish NK; Shanta Kumar SM; Mayur YC
Chem Biol Interact; 2008 Nov; 176(2-3):212-9. PubMed ID: 18638463
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 2-fluoro N(10)-substituted acridones and their cytotoxicity studies in sensitive and resistant cancer cell lines and their DNA intercalation studies.
Mayur YC; ; Peters GJ; Lemos C; Kathmann I; Prasad VV
Arch Pharm (Weinheim); 2009 Nov; 342(11):640-50. PubMed ID: 19856333
[TBL] [Abstract][Full Text] [Related]
4. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
Kelly JX; Smilkstein MJ; Cooper RA; Lane KD; Johnson RA; Janowsky A; Dodean RA; Hinrichs DJ; Winter R; Riscoe M
Antimicrob Agents Chemother; 2007 Nov; 51(11):4133-40. PubMed ID: 17846138
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide releasing acridone carboxamide derivatives as reverters of doxorubicin resistance in MCF7/Dx cancer cells.
Rajendra Prasad VV; Deepak Reddy G; Kathmann I; Amareswararao M; Peters GJ
Bioorg Chem; 2016 Feb; 64():51-8. PubMed ID: 26657603
[TBL] [Abstract][Full Text] [Related]
7. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitizing acridones: in vitro calmodulin dependent cAMP phosphodiesterase inhibition, docking, pharmacophore modeling and 3D QSAR studies.
Rajendra Prasad VV; Deepak Reddy G; Appaji D; Peters GJ; Mayur YC
J Mol Graph Model; 2013 Mar; 40():116-24. PubMed ID: 23388503
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells.
Głowacka-Rogacka D; Arciemiuk M; Kupiec A; Bontemps-Gracz MM; Borowski E; Tarasiuk J
Cancer Detect Prev; 2004; 28(4):283-93. PubMed ID: 15350632
[TBL] [Abstract][Full Text] [Related]
11. Combined Fourier transform infrared and Raman spectroscopic approach for identification of multidrug resistance phenotype in cancer cell lines.
Krishna CM; Kegelaer G; Adt I; Rubin S; Kartha VB; Manfait M; Sockalingum GD
Biopolymers; 2006 Aug; 82(5):462-70. PubMed ID: 16493658
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents.
Murahari M; Kharkar PS; Lonikar N; Mayur YC
Eur J Med Chem; 2017 Apr; 130():154-170. PubMed ID: 28246041
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
14. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
16. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Gopinath VS; Thimmaiah P; Thimmaiah KN
Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxic activity of novel protoflavone analogs - selectivity towards a multidrug resistant cancer cell line.
Danko B; Martins A; Chuang DW; Wang HC; Amaral L; Molnár J; Chang FR; Wu YC; Hunyadi A
Anticancer Res; 2012 Jul; 32(7):2863-9. PubMed ID: 22753749
[TBL] [Abstract][Full Text] [Related]
18. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
Ford JM; Prozialeck WC; Hait WN
Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
[TBL] [Abstract][Full Text] [Related]
19. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of a naturally occurring furoquinoline alkaloid and four acridone alkaloids towards multi-factorial drug-resistant cancer cells.
Kuete V; Fouotsa H; Mbaveng AT; Wiench B; Nkengfack AE; Efferth T
Phytomedicine; 2015 Sep; 22(10):946-51. PubMed ID: 26321744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
